The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) — formerly known as cilta-cel — for certain adults with relapsed or refractory multiple myeloma. In particular, the approval makes Carvykti available for people who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and a CD38 inhibitor. The decision comes about eight months after the FDA granted priority review to the Carvykti application. The…
You must be logged in to read/download the full post.
The post Cilta-cel – now Carvykti – Approved by FDA for Heavily-treated Myeloma appeared first on BioNewsFeeds.